NEUROFIBROMATOSIS RESEARCH PROGRAM



DECREASE THE CLINICAL IMPACT OF NEUROFIBROMATOSIS

Mission: Promote research directed toward the understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis to enhance the quality of life for persons with these disorders that impact Service Members, Veterans, and the general public

FY24 Appropriation

FY24 Mechanisms and Funding Amounts



Neurofibromatosis Research Academy -Leadership Award



800K/ Clinical Trial Award



Early Investigator Research Award



\$100K **Exploration-Hypothesis Development Award**



^{\$}525K/

Investigator-Initiated Research Award



New Investigator Award



combined Synergistic Idea Award FY96-FY23 524 Awards*

NF2 projects \$68.8M 19%

12 NF1/NF2/ Schwannomatosis projects \$31.3M | 2%

6 NF1/Schwannomatosis projects \$3.2M | 1%

11 NF1/NF2 projects \$14M | 4%

> 351 NF1 projects \$213.1M 67%

524 **Total Projects**

36 Schwannomatosis projects \$21.8M 7%

11 NF2/Schwannomatosis projects \$8.9M I 2%

FY24 Application Deadlines

Neurofibromatosis Research Academy Deadlines

August 22, 2024 Letter of Intent Submission Deadline

Application Submission Peer Review Deadline

September 12, 2024 November 2024

January/ February 2025 Programmatic Review

Other Mechanism Deadlines

September 12, 2024 October 3, 2024 Letter of Intent Submission Deadline

Application Submission

December 2024 Peer Review

February 2025 Programmatic Review

FY24 Areas of Emphasis

Neurofibromatosis Type 2 and Schwannomatosisrelated areas

Endpoint validation, biomarker discovery, and technological innovation for assessments

Application of data science

Non-tumor manifestations not limited to pain, cognitive manifestations, sleep

Heterogeneity of NF-related phenotypes

Genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches

Preclinical efficacy studies

Target identification and drug discovery

Nutritional, environmental, and other modifiers of NF

Health services research





^{*} FY23 awards are included in the total number of projects. FY23 awards are still under negotiation and will be confirmed by 9/30/2024.